Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September.  | In new ...

With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...

This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...

TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...